Abstract
Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Current Neuropharmacology
Title:Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models
Volume: 10 Issue: 3
Author(s): Akiyoshi Saitoh and Mitsuhiko Yamada
Affiliation:
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Abstract: Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Export Options
About this article
Cite this article as:
Saitoh Akiyoshi and Yamada Mitsuhiko, Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217314
DOI https://dx.doi.org/10.2174/157015912803217314 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry TLR2 and TLR4 Expression During Bacterial Infections
Current Pharmaceutical Design Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Therapeutic Properties of Several Chemical Compounds of <i>Salvia officinalis</i> L. in Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Comparative Genomics for the Investigation of Autoimmune Diseases
Current Pharmaceutical Design Link Between Chronic Bacterial Inflammation and Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Sex, Stress and their Influence on Respiratory Regulation
Current Pharmaceutical Design miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Structure, Activities and Biomedical Applications of Human Butyrylcholinesterase
Protein & Peptide Letters Mechanisms of the Blunting of the Sympatho-Adrenal Response: A Theory
Current Diabetes Reviews Crosstalk between Inflammation and the BBB in Stroke
Current Neuropharmacology Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Current Neuropharmacology Ubiquitin Carboxyl Hydrolase L1 Significance for Human Diseases
Protein & Peptide Letters Nicotine Effects, Body Weight Concerns and Smoking: A Literature Review
Current Pharmaceutical Design Actual Knowledge of Systemic Inflammation Reaction During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery